Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Lowell Therapeutics
- Ownership
- Private
- Development stage
- Other
01
Overview
Lowell Therapeutics' lead asset, Niyad, is a lyophilized formulation of nafamostat, a synthetic serine protease inhibitor acting as a regional anticoagulant for dialysis circuits. It received FDA Breakthrough Device Designation and is not yet commercialized in the U.S., though the active drug has approval in Japan and South Korea for related indications. No FDA-approved products currently exist for this indication in the U.S.[3][5][9]
- Therapeutic areas
- NephrologyHematologyGastroenterologyPulmonology
- Modalities
- Small moleculeSynthetic serine protease inhibitor
- Industry
- Biotech
Beyond the preview
Go deeper on Lowell Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lowell Therapeutics.